North Point Portfolio Managers Corp OH Decreases Position in Boston Scientific Corporation $BSX

North Point Portfolio Managers Corp OH reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 19.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 108,023 shares of the medical equipment provider’s stock after selling 26,202 shares during the quarter. North Point Portfolio Managers Corp OH’s holdings in Boston Scientific were worth $4,715,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Boston Scientific in the second quarter valued at $5,534,781,000. State Street Corp boosted its position in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the 2nd quarter worth about $2,156,233,000. Jupiter Topco LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $803,357,000. Finally, Janus Henderson Group PLC grew its stake in shares of Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after buying an additional 3,907,981 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 194,522 shares of company stock worth $9,385,210 over the last quarter. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday, September 17th. Barclays initiated coverage on Boston Scientific in a research note on Tuesday. They issued an “equal weight” rating and a $48.00 price objective for the company. Mizuho dropped their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, UBS Group decreased their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $66.31.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.03 during trading on Wednesday, reaching $42.22. 7,368,055 shares of the stock traded hands, compared to its average volume of 18,659,338. Boston Scientific Corporation has a 52-week low of $41.81 and a 52-week high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a 50-day moving average of $46.81 and a 200-day moving average of $51.11. The stock has a market capitalization of $61.18 billion, a P/E ratio of 17.07, a price-to-earnings-growth ratio of 1.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.